Brace Pharma — 2021 Investments

1 investments dated 2021 · listed companies and verified rows first · show all

Gliknikgliknik.comMay 2021

Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.

BiotechBaltimore, US

David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Mark Lerner(Director)

BoardCharles Polsky(Director)

Co-investorsFirst In Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.